Novavax’s Experimental COVID-19 Vaccine Has 96% Efficacy Rate, Drugmaker Says

by Jeremy

Maryland-based drugmaker Novavax announced Thursday that its experimental COVID-19 vaccine appears to be highly effective in combating the coronavirus, raising hopes that a fourth vaccine could be available in the U.S. in the coming months.  Citing results of phase 3 clinical trial conducted in the United Kingdom, Novavax said its vaccine was more than 96% effective against “mild, moderate and severe disease caused by the original COVID-19 strain” and 86% effective against the more contagious B.1.1.7 variant, which was first detected in the U.K. and has sickened at least 3,7000 people in the U.S. to date.


Novavax said the vaccine was found to be 100% effective in preventing severe disease, no matter the variant — an efficacy rate comparable to that of Moderna’s and Pfizer’s vaccines, which are both in use in the United States.

The Johnson & Johnson COVID-19 vaccine, approved last month by the Food and Drug Administration, has a reported efficacy rate of 86% against severe disease.

Novavax CEO Stanley Erck said in a statement that the company was “very encouraged by the data” from the clinical trial in the U.K., which involved 15,000 participants and a phase 2b trial conducted in South Africa.  Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19,” Erck said.

Related Posts

Leave a Comment